Pharmaceuticals group Elan expects to finalise the introduction of its Frova treatment for acute migraine by the end of the year, following the approval of the treatment by the US Food and Drugs Administration.

Elan licensed exclusive North American sales and distribution rights for Frova from the British group Vernalis in October 1998.